Interferon for postresection recurrence of hepatocellular carcinoma

American Journal of Gastroenterology

Volumn 97, Issue 12, 2002, Pages 3200-3202

  Mallat, Damien B ^a   El Serag, Hashem B ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; NOTE; PRIORITY JOURNAL; SURVIVAL;

EID: 0036895059     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)05550-8     Document Type: Note

References (10)

1. El-Serag HB. Global epidemiology of hepatocellular carcinoma. Liver Clin N Am 2001;5:87-107.
2. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
3. Shindo M, Hamada K, Oda Y, et al. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 2001;33:1299-302.
4. Camma C, Giunta M, Andreone P, et al. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol 2001;34:593-602.
5. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: A meta-analysis. Aliment Pharmacol Ther 2001;15:689-98.
6. Merle P, Chevallier M, Levy R, et al. Preliminary results of interferon-alpha therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: Possible benefit in female transgenic mice. J Hepatol 2001;34:562-9.
7. Moriyama Y, Nishiguchi S, Tamori A, et al. Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma. Clin Cancer Res 2001;7:1293-8.
8. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:436-8.
9. Kubo S, Hirohashi K, Tanaka H, et al. Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. World J Surg 2000;24:1559-65.
10. Oon CJ. Long-term survival following treatment of hepatocellular carcinoma in Singapore: Evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992;31(suppl):S137-42.